Molecular Tests May Aid Clinical Decision-Making and Reduce Healthcare Costs.

The author discusses the benefits of molecular tests in making treatment decisions regarding prostate cancer. He examines the results of a retrospective analysis which suggest that the Prostate Core Mitomic Test (PCMT) may aid clinical decision making, which may result in a reduced need for repeat biopsy. He also describes the economic and quality of life benefits of molecular tests for payers who avoid the need for repeated biopsies.